

084875.89

-2-

In the Specification

Please replace the Related Applications Paragraph on page 1 with the following paragraph:

This application is the U.S. National Phase of PCT/US96/02153, filed February 12, 1996 and is a continuation-in-part of U.S. Serial No. 08/523,004 (Attorney Docket No. LKS94-04A), filed on September 1, 1995, the teachings of which are each incorporated herein by reference in their entirety.

Amendments to the specification are indicated in the attached "Marked Up Version of Amendments" (page i).

In the Claims

Claims 33, 34, 37, 38, 44, 46, 89-93 and 94-100 drawn to non-elected inventions (Paper No. 18 at page 2, Paragraph No. 2) and Claims 102, 104, 110, 114 and 123 have been cancelled without prejudice. Claims 24, 103, 107-109, 113, 120-122, 126, 128, 129, 131, 133 and 134 have been amended and are presented below in amended form and Claims 136-160 are new. In accordance with 37 C.F.R. § 1.121(c)(1)(ii), amendments to the claims are indicated in the attached "Marked Up Version of Amendments" (pages i-iv).

24. (Twice Amended) A fusion protein comprising a naturally occurring primate MAdCAM, wherein said naturally occurring primate MAdCAM binds $\alpha 4\beta 7$ integrin and has at least about 55% amino acid sequence similarity to an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:6.

103. (Amended) The fusion protein of Claim 24 wherein said naturally occurring primate MAdCAM has at least about 75% amino acid sequence similarity to an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:6.